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hydrochloride (KY-109) was synthesized as a bifunctional pro-drug designed to improve the oral absorption of the parent drug (KY-087), a cephalosporin similar in activity to cefamandole.
The pro-drug was found to possess the desired factors for an orally active pro-drug, that is, appropriate solubility, lipophilicity and ease hydrolysis into the parent drug. As predicted from these factors, the pro-drug when administered orally to rats was well absorbed, and gave high blood levels of the parent drug.
7-(n-Mandelamido)-3-[[(5-methyl-1,3,4-thiadiazol-2-yl)thio]methyl]-3-cephem-4-carboxylic acid
(KY-087)1) is a cephalosporin with a broad spectrum of antibacterial activity in vitro. It is, however, poorly absorbed from the gastro-intestinal tract after oral administration, probably due to its low lipo-
philicity. An ester pro-drug approach is frequently utilized as a method for increasing the lipophilicity of a drug and thereby improving its absorption after oral administration. A j5-lactam antibiotic containing a relatively basic amino group can give an ester with high lipophilicity and sufficient aqueous solubility, which is significantly better absorbed orally than the parent drug1). Examples of such successful compounds are the pivaloyloxymethyl3), 1-ethoxycarbonyloxyethyl4), phtalidyl5) and (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl6) esters of ampicillin.
In contrast, esters of 3-lactam antibiotics lacking a basic amino group in the side chain, such as KY-087, generally seem to be weakly active when given orally, probably because they lack sufficient solubility in water for efficient absorption from the gastro-intestinal tract to occur2,7). To overcome the low aqueous solubility of such esters of KY-087, we have prepared the bifunctional pro-drug, (5-methyl-2-oxo-1,3
-dioxol-4-yl)methyl 7-[D-O-(L-alanyl)mandelamido]-3-
[[(5-methyl-1,3,4-thiadiazol-2-yl)thio]methyl]-3-cephem-4-carboxylate hydrochloride, having in addition to the ester group in the 4-position an L-alanine ester formed with the side chain a-hydroxyl group. Due to the amino group in the alanine residue, the bifunctional pro-drug might be expected to have increased aqueous solubility along with a lipophilic character.
In this report we describe the physico-chemical and biological properties of the bifunctional prodrug KY-109 in comparison with those of the parent drug (KY-087) and the monofunctional pro-drug (KY-106) having only the ester group in the 4-position. 
Chemistry
Three general pathways were followed in the synthesis of KY-109 (Chart 2). In one of these (method A) the starting material was KY-087, which was treated with 4-bromomethyl-5-methyl- 
Results
In Vitro Antibacterial Activity
The in vitro antibacterial activity of the parent drug KY-087 was compared with that of the widely used oral cephalosporins, i.e., cefaclor (CCL) and cephalexin (CEX), and of the parenteral cephalosporin, cefamandole (CMD) ( to the extent of 500 mg/ml or greater, whereas KY-106 had a very low solubility. The lipophilicity, expressed as the partition coefficient between 1-octanol and pH 6.5 phosphate buffer, was 39.0 for KY-106 and 7.8 for KY-109, compared with less than 0.01 for KY-087.
KY-109 was hydrolyzed to the parent drug in serum and intestinal homogenate of the rat, with halflives of 3.7 and 2.2 minutes, respectively ( Table 2 ).
The stability of KY-109 at pH values between 2 and 7, measured at 35°C by determining residual intact pro-drug, is shown in Fig. 1 . The compound was stable in acidic solution but was rather rapidly destroyed in neutral solution, with a half-life of 1.1 hours.
Oral Absorption in Rats
The absorption of KY-109 after oral administration of a dose equivalent to 25 mg/kg of KY-087 to (Table 3) . KY-087 sodium and KY-106 when administered orally were poorly absorbed and the peak levels in plasma were 1.1 ,ug/ml and 0.9 ,ug/ml respectively, while KY-109 was absorbed rapidly and efficiently from the gastro-intestinal tract, the peak level being 13.6 jig/ml at 30 minutes. The bioavailability after oral administration (AUCpo/ AUCKY-087iv) was 30.7 % for KY-109, compared with 3.5% for KY-087 sodium and 1.5% for KY-106. drugs, aqueous solubility and lipophilicity are known to be important factors2). In addition to having the desired lipophilicity and solubility properties, the pro-drug must possess an optimal lability. It must be stable in the gastro-intestinal lumen but should, upon absorption, be rapidly hydrolyzed to the parent drug. In this study, KY-087 (the parent drug) is poorly absorbed orally in rats, probably due to a poor lipophilicity.
KY-106 (the monofunctional pro-drug) in which only the strongly acidic 4-carboxyl group of KY-087 has been esterified has a very low solubility in water, although it has a high lipophilicity. Therefore, the incomplete absorption of KY-106 is probably attributed to its poor solubility in the gastro-intestinal fluids. In contrast, KY-109 (the bifunctional pro-drug), in which, in addition to the 4-carboxyl ester, the side chain a-hydroxyl group has been esterified with L-alanine, containing a hydrophilic amino group, combines an increased lipophilicity with a good aqueous solubility.
Furthermore, it is hydrolyzed to the parent drug in the presence of serum and intestinal homogenate.
Thus, KY-109 was found to possess properties with regard to lipophilicity, aqueous solubility and hydrolysis in biological fluids that should make it an orally active pro-drug. When administered orally to rats, KY-109 was well absorbed, giving high blood levels of the parent drug. Although the exact mechanism of absorption of the bifunctional pro-drug has not been elucidated, it is reasonable to assume that, during or shortly after absorption of the pro-drug into the blood-stream from the gastro-intestinal tract both the L-alanyl and the (5-methyl-2-oxo-l,3-dioxol-4-yl)methyl residues are split off enzymatically with the formation of the parent drug.
Experimental
Melting points were determined with a Yamato MP-21 apparatus and are uncorrected. The NMR spectra were obtained on a Hitachi R-600 spectrometer. IR spectra were obtained in Nujol on a Shimadzu IR-400 spectrometer, and the main absorptions are given in cm-1. Chemical analysis was performed by the microanalytical group of Kyoto University.
4-Bromomethyl-5-methyl-l,3-dioxol-2-one (15.5 g) was added to a stirred mixture of KY-087 (34 g) and potassium acetate (7.0 g) in DMF (120 ml) at -20°C. After 1 hour, ethyl acetate (300 ml) was added to the reaction mixture and the obtained organic phase was washed with water followed by brine, and dried over Na2SO4. The filtered organic solution was evaporated in vacuo and the residue crystallized from methanol to give 22 g of KY-106 (2); mp 151°C (dec); IR (Nujol) 3350, 1820, 1780, 1730, 1680 cm-1; NMR (acetone-d6) 5 
A mixture of 7-ACTD K (100 g) and ethyl acetoacetate (500 ml) was stirred at room temperature overnight. The resulting crystalline precipitate was filtered off, washed with ethyl acetate and added to a solution of 4-bromomethyl-5-methyl-1,3-dioxol-2-one (46 g) in DMF (400 ml) at -5~0°C.
After stirring for 1 hour, aqueous methanol (10%, 440 ml) was added to the reaction solution, and stirring continued at room temperature for 30 minutes. The resulting precipitate was filtered off, washed with water followed by methanol and crystallized from dichloromethane-methanol to give 120 g of 4; mp 150°C (dec); IR (Nujol) 1820, 1780, 1725, 1640, 1610 cm-1; NMR (acetone-d6) Compound 4 (100 g) dissolved in dichloromethane (500 ml) was treated with methanol (25 ml) and cone HCl (30 ml) and stirred at 10~15°C for 4 hours. The resulting precipitate was filtered off, dissolved in water (500 ml) and washed with ethyl acetate. The aqueous layer was added to dichloromethane (500 ml) and NaHCO3 (45 g) was added under stirring. The separated organic solution was washed with brine, dried over Na2SO4 and evaporated in vacuo. The residue was crystallized from dichloromethane -ethyl acetate to yield 60 g of 5; mp 108°C (dec); IR (Nujol) 3400, 3350,1810, 1780, 1730 cm-1; NMR (DMSO-d6) 8 2.18 (s, 3H, dioxole-CH3), 2.6 (br, 2H, NH2), 2.67 (s, 3H, thiadiazole-CH3), 3 
) and triethylamine (9 ml) were dis- ) and triethylamine (9.5 ml) in a mixture of tetrahydrofuran (300 ml) and water (200 ml) was added at -10°C, and the mixture stirred at 0°C for 1 hour and for a further hour at room temperature.
The solvent was removed under reduced pressure and the residue was acidified with dilute H3PO4 and extracted with ethyl acetate. The organic layer was washed with water, dried over Na2SO4 and evaporated in vacuo to give a residue, which was purified by silica gel column chromatography with chloroform -methanol (5: 1) to give 20 g of 7; IR (Nujol) 3300, 1780, 1760, 1690 cm-1; NMR (DMSO-d6) 8 1.30 (d, 3H, J=7 Hz, CHCH3), 1.35 (s, 9H, C(CH3)3),  2.67 (s, 3H, thiadiazole-CH3), 3.45 (br s, 2H, 2-H2), 3.91~4.75 (m, 4H, 3-CH2S, COOH, CHCH3 ), 4.96 (d, 1H, J=5 Hz, 6-H), 5.64 (dd, 1H, J=5 and 9 Hz, 7-H), 6.02 (s, 1H, CHCONH), 7.39 (s, 5H, Ph), 9.27 (d, 1H, J=9 Hz, CONH).
Method A: KY-106 (2.75 g) and N-(tert-butoxycarbonyl)-L-alanine (0.97 g) were dissolved in dichloromethane (100 ml), and DCC (1.15 g) and 4-dimethylaminopyridine (60 mg) were added to the solution at 0°C. After stirring at the same temperature for 1 hour, the precipitated dicyclohexylurea (DCU) was removed. The filtrate was washed with 10% aqueous citric acid and brine, dried over Na2SO4 and evaporated in vacuo. The residue was crystallized from methanol to give 3.3 g of the intermediate (8).
Method B: A solution of DCC (10.8 g) in dichloromethane (10 ml) was added dropwise to a solution of 5 (20.4 g) and 6 (17 g) in dichloromethane (160 ml) at -10~0°C.
After stirring for 1 hour, the precipitated DCU was removed and the filtrate was evaporated in vacuo. The residue was crystallized from methanol to give 21.2 g of the intermediate (8).
Method C: A solution of 4-bromomethyl-5-methyl-l,3-dioxol-2-one (2.33 g) in DMF (15 ml) was added to a mixture of 7 (6.5 g) and potassium acetate (0.98 g) at -10°C.
After stirring for 30 minutes, water (100ml) was added and the reaction mixture was extracted with ethyl acetate (2 x 50 ml). The combined oragnic layers were washed with brine, dried over Na2SO4 and evaporated in vacuo. The residue was crystallized from methanol to give 6. 
Test Antibiotics
Cefamandole, cephalexin and cefaclor (Shionogi & Co., Ltd.) were commercial products. KY-087 sodium was prepared using the method described by HoovER1).
Determination of MICs
Minimum inhibitory concentrations (MICs) were determined by the agar dilution method, using Mueller-Hinton agar (MHA). Serial two-fold dilutions of freshly prepared antibiotic solutions were THE JOURNAL OF ANTIBIOTICS MAR. 1985 mixed with melted MHA in Petri dishes. Plates were inoculated with one loopful of 10-2 fold diluted overnight culture of the test organisms in Mueller-Hinton broth (MHB) unless otherwise described. The MIC values (jig/ml) were determined after 18 hours of incubation at 37°C.
Absorption Studies
Male Wistar strain rats weighing 180~220 g were used. Before the experiment, the animals were starved overnight but were allowed to drink water. KY-087 was administered orally or intravenously as an aqueous solution of the sodium salt, at a dose 25 mg/kg, to the test animals. KY-106 and KY-109 were given orally at a dose equivalent to 25 mg/kg of KY-087 as an aqueous suspension and an aqueous solution, respectively.
Blood samples were collected from the jugular vein at specified intervals after administration. The antibiotic concentrations in the plasma were bioassayed using standard solutions prepared with control plasma of rats. Bioassay was performed by the agar-well method with B. subtilis as the test organism.
Aqueous Solubility
The aqueous solubilities of the compounds were estimated at 25°C by shaking an excess of each with 10 ml of water, for a time period limited to 3 hours to minimize degradation of the compounds. The saturated solutions were filtered, diluted, and the concentrations of the compounds measured by the highperformance liquid chromatographic (HPLC) method (Waters ALC/GPC conpact type, model 440 detector, 245 nm filter, model 45 pump, model WISP 710B injector, and reverse phase Radial Pac pBondapac C column). Elution was carried out with aqueous KH2PO4 (0.3 %) -CH,CN (80: 20 for KY-087, and 60 :40 for KY-109 and KY-106) at a flow rate of 0.3 ml/minute. Partition Coefficient Solution of 1.5 x 10-2 mM of a compound was prepared in 100 ml of 1/15 M phosphate buffer (pH 6.5) saturated with 1-octanol. The solution (10 ml) was put into a test tube containing l-octanol (5 ml) saturated with pH 6.5 buffer. The test tube was shaken vigorously at 25°C. When equilibrium had been achieved (1 hour), the aqueous layer was separated by centrifugation, and the concentration of the drug was measured by HPLC method similar to that described for the aqueous solubility.
In Vitro Hydrolysis In Buffer Solutions: KY-109 was added to an appropriate buffer solution (pH 2~6, 0.1 M citrate; pH 6~7, 0.1 M phosphate) at 50 Fig/ml, and the solutions were maintained at 35°C. Samples were withdrawn at proper intervals and the remaining intact KY-109 was determined by the HPLC method (Shimadzu LC-3A, SPP-2A detector, 270 nm filter and reverse phase Unisil Q C18 column). Elution was carried out with aqueous 0.05 M KH2PO4 -CH3CN (60: 40) at a flow rate of 2.0 ml,/minute.
In Intestine Homogenate:
The small intestine was obtained from a freshly killed rat and was immediately thoroughly washed with cold saline to remove any contents. It was homogenized at 31.5 % w/v in ice-cold saline, using an Ultra Disperser (LK-21, Yamato). KY-109 was dissolved in saline at a concentration equivalent to 200,ug/ml of the parent cephalosporin.
The solution (1 ml) was rapidly added to the intestinal homogenate (19 ml) to give a reaction mixture with KY-109 at final concentration of 10 pg/ml in 30 % w/v homogenate that was incubated at 37°C and sampled at 2, 5, 15, 30 and 60 minutes after mixing. Samples of 3 ml were poured into a mixture of pH 7.4 phosphate buffer (1 ml) and dichloromethane (3 ml) and shaken vigorously. The aqueous phase was separated and assayed for the resulting parent compound by the agar-well method with B. subtilis ATCC 6633 as the test organism.
